insights_auto
Zašto je NSIS-B skočio 2,47%?
Istražite detaljnijechevron_right
NSIS-B:CPH
Novozymes A/S
460,10 DKK
arrow_upward
+2,47%(+11,10) 1D
15. lis, 14:29:09 GMT+2 · DKK
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za NSIS-B...
Otvori
454,10 DKK
Najviša
460,80 DKK
Najniža
452,40 DKK
Trž. kap.
183,47 mlr.
Prosj. kol.
567,49 tis.
Količina
189,28 tis.
52-tjed. najviša
465,00 DKK
52-tjed. najniža
336,80 DKK
Dionice u optjecaju
414,56 mil.
Broj djelatnika
11 tis.
Otvori
454,10 DKK
Najviša
460,80 DKK
Najniža
452,40 DKK
Trž. kap.
183,47 mlr.
Prosj. kol.
567,49 tis.
Količina
189,28 tis.
52-tjed. najviša
465,00 DKK
52-tjed. najniža
336,80 DKK
Dionice u optjecaju
414,56 mil.
Broj djelatnika
11 tis.
Vijesti
Iz web-izvora i od partnera za vijesti
ad-hoc-news.de
·
prije 40 minuta
Novonesis stock stands 1.27 percent below its 52-week high
Profil
Novonesis is a biotechnology company headquartered in Lyngby, Denmark. Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen.
The company develops enzymes, microbial cultures, and other biological products used in food and beverage production, household products, agriculture, and bioenergy.
The merger, first announced in December 2022, was the largest merger in history between two Danish companies. It would combine Novozymes' industrial-enzyme business with Chr. Hansen's microbial cultures and food-ingredient operations.
The company is publicly traded on Nasdaq Copenhagen and is part of the OMX Copenhagen 25 Index. The company's largest shareholder is Novo Holdings A/S, which is owned by the Novo Nordisk Foundation.
As of 2025, Novonesis has more than 11,000 employees and activities in over 45 countries. Wikipedia
Novozymes A/S – informacije
Glavni izvršni direktorEster Baiget
Zaposlenici11,1 tis.
Osnovano2000
Sjedište-
SektorSpeciality chemicals
Web-lokacijanovonesis.com